We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Apoptosis Inhibitors Are Biomarkers for Ovarian Cancer Prognosis

By Biotechdaily staff writers
Posted on 05 Dec 2007
Cancer researchers have found that contrary to expectations, expression of proteins linked to tumor cell survival were actually biomarkers for improved patient survival in ovarian cancer.

Investigators at the [U.S.] National Cancer Institute (Bethesda, MD, USA) employed immunohistochemical analysis to study the expression patterns of BAG-1, BAG-3, BAG-4, and Bcl-xL proteins in tissue samples obtained at diagnosis from 28 women with stage III or stage IV ovarian cancer undergoing chemotherapy with platinum-based drugs. More...
These proteins are all known for inhibiting apoptosis and promoting tumor growth. Association of these proteins, as well as BAG-6, heat shock protein 70 (Hsp70), Hsp27, and Bcl-2 was then tested in ovarian cancer tissue arrays.

Results published in the November 15, 2007, issue of Clinical Cancer Research revealed that elevated cytoplasmic expression of BAG-4 was strongly and positively associated with long-term patient survival (both overall and progression-free survival). Bcl-2 staining was significantly more frequent on the tissue array in lower stage and grade tumors, whereas Hsp70 was prominent in higher-grade cases. Furthermore, Bcl-xL was more closely associated with serous compared with endometrioid ovarian cancers.

"We selected these proteins for study assuming that, because of their known abilities to promote the survival of cancer cells, they would likely correlate with worse clinical outcomes and high tumor aggressiveness,” said senior author Dr. Elise Kohn, head of the molecular signaling section at the [U.S.] National Cancer Institute. "We did not expect to find that increased expression of these proteins would actually be linked with better survival.”


Related Links:
[U.S.] National Cancer Institute

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.